Tech Company Financing Transactions
IRX Therapeutics Funding Round
IRX Therapeutics, operating out of New York, secured $25 million in funding from private investors.
Transaction Overview
Company Name
Announced On
6/3/2008
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Proceeds Purpose
The new funding will be used to further develop its cancer and viral disease product platform, including IRX-2 (citoplurikin), the Company's lead candidate for cancer treatment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
654 Madison Ave. 1601
New York, NY 10065
USA
New York, NY 10065
USA
Phone
Website
Email Address
Not Recorded
Overview
IRX Therapeutics' mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Leuchtenberger
Chief Financial Officer
Curtis Robb
Chief Operating Officer
Monil Shah
Chief Scientific Officer
Neil Berinstein
VP - Regulatory Affairs
Zygmund Roth
Browse more venture capital transactions:
Prev: 6/3/2008: Solicore venture capital transaction
Next: 6/3/2008: Ekahau venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs